Metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8858916-B2
Publication Date
2014-10-14
Expiration Date
Abstract
A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.
Core Innovation
The invention provides a metallopharmaceutical hexose derivative compound of a formula in which R8 comprises one or more metal ions. The described metallopharmaceutical constructs include a glucose carrier linked such that the metal-coordinating moiety is attached to the glucose at the C-6 position, including by a secondary amine linker to a tertiary-amine metal coordinating moiety.
The disclosure addresses metallopharmaceutical glucose conjugates in which the IDA metal coordinating moiety and the DTPA metal coordinating moiety are conjugated to a hexose or glucose carrier at the C-6 position. The described structures include specific glucose-chelator conjugate structures such as DOTA/DOTA-amine-glucose, iminodiacetic-acid 6-aminoglucose, and DTPA-6-aminoglucose, with examples referenced for DOTA 6-aminoglucose and formula 12 and formula 13.
The patent further describes generalized synthetic schemes for coupling metal-coordinating moieties and hexose via protected intermediates, together with broader pharmaceutically acceptable carrier and administration route discussion. It also includes radiolabeling and kit composition guidance, including kit components and buffers such as citrate, phosphate, and borate, and stabilization aids such as lyophilization.
Claims Coverage
The independent claim covers a metallopharmaceutical hexose derivative compound defined by a formula in which R8 comprises one or more metal ions. The dependent claims refine R8 to enumerated sets of metal radionuclides/elements and further to a single defined metal, 111 Indium.
Metallopharmaceutical hexose derivative with metal ions in R8
A metallopharmaceutical hexose derivative compound of the formula in which R8 comprises one or more metal ions.
R8 selected from an enumerated group of metal radionuclides/elements
The compound further specifies that R8 is selected from a listed group of metal radionuclides/elements.
R8 narrowed to a smaller enumerated subset
The compound is defined such that R8 is selected from Gallium, Lutetium, Yttrium, Indium, Indium (113m), Technetium, Technetium (99m), Rhenium, and Rhenium (188).
R8 equals 111 Indium
The compound is defined such that R8 equals indium (111 Indium).
Overall, claim coverage centers on metallopharmaceutical hexose derivative compounds where the metal-binding portion is captured in R8, and the scope is progressively narrowed by selecting R8 from specified metal radionuclides/elements, ultimately to 111 Indium.
Stated Advantages
Enables cellular uptake via the hydrogen-donor/hydrogen-acceptor characterized linker.
Provides long cellular retention for imaging.
Shows non-significant intracellular metabolism.
Enables efficient excretion.
Avoids metal deposition.
Documented Applications
Imaging modalities including SPECT, CT/CAT, MRS, MRI, PET, fluorescence, and x-ray are described in connection with long cellular retention for imaging.
Interested in licensing this patent?